Dextromethorphan phenotyping and haloperidol disposition in schizophrenic patients

The UKU side effect rating scale: A new comprehensive rating scale for psychotropic drugs and a cross‐sectional study of side effects in neuroleptic‐treated patients

1987 • 1,610 citations

A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.

1980 • 544 citations

Polymorphic dextromethorphan metabolism: Co-segregation of oxidative O-demethylation with debrisoquin hydroxylation

1985 • 386 citations

Pharmacokinetics of Haloperidol

1989 • 292 citations

Molecular basis of genetic variation in debrisoquin hydroxylation in Chinese subjects: Polymorphism in RFLP and DNA sequence of CYP2D6

1993 • 159 citations

Haloperidol Disposition Is Dependent on Debrisoquine Hydroxylation Phenotype

1992 • 157 citations

Metabolites of haloperidol display preferential activity at σ receptors compared to dopamine D-2 receptors

1990 • 149 citations

Polymorphic debrisoquin hydroxylation in 757 Swedish subjects

1988 • 135 citations

Neuroleptic dosage for Asians

1983 • 112 citations

Haloperidol Blood Levels and Clinical Effects

1992 • 112 citations

Oxidation of reduced haloperidol to haloperidol: involvement of human P450IID6 (sparteine/debrisoquine monooxygenase).

1991 • 106 citations

Haloperidol Disposition Is Dependent on the Debrisoquine Hydroxylation Phenotype

1992 • 99 citations

Haloperidol reductase in human and guinea pig livers.

1989 • 83 citations

Extrapyramidal reactions in Asians

1981 • 83 citations

Determination of dextromethorphan metabolizer phenotype in healthy volunteers

1989 • 56 citations

Review of Haloperidol Blood Level and Clinical Response

1987 • 53 citations

Assessment of the debrisoquin and dextromethorphan phenotyping tests by gaussian mixture distributions analysis

1989 • 50 citations

Haloperidol and reduced haloperidol plasma levels in Chinese vs. non-Chinese psychiatric patients

1989 • 49 citations

Polymorphism of dextromethorphan oxidation in a French population.

1987 • 48 citations

High-Performance Liquid Chromatography Determination of Dextromethorphan and Dextrorphan for Oxidation Phenotyping by Fluorescence and Ultraviolet Detection

1993 • 40 citations

Pharmacodynamics and pharmacokinetics of haloperidol and reduced haloperidol in schizophrenic patients

1989 • 37 citations

A multidimensional (pharmacokinetic and clinical-biological) approach to neuroleptic response in schizophrenia

1993 • 37 citations

Reduced haloperidol: a factor in determining the therapeutic benefit of haloperidol treatment?

1992 • 30 citations

Dextromethorphan Polymorphic Hepatic Oxidation (CYP2D6) in Healthy Black American Adult Subjects

1995 • 29 citations

Comparison of the prevalence of the poor metabolizer phenotype for CYP2D6 between 203 Hmong subjects and 280 white subjects residing in Minnesota*

1995 • 26 citations

Low frequency of dextromethorphan O-demethylation deficiency in a Chinese population*

1996 • 18 citations

Haloperidol plasma concentrations in Taiwanese psychiatric patients.

1995 • 13 citations

Dose-dependent reduced haloperidol/haloperidol ratios in schizophrenic patients

1991 • 12 citations

Haloperidol kinetics and clinical response

1991 • 11 citations

Dextromethorphan O-demethylation polymorphism in Jordanians

1993 • 10 citations

Development of an ELISA to study the polymorphism of dextromethorphan oxidation in a french population

1990 • 10 citations

Pharmacogenetics of Agents Acting on the Central Nervous System

1993 • 2 citations

Cited By (0)

No citing papers found in database